<DOC>
	<DOCNO>NCT01843374</DOCNO>
	<brief_summary>This Phase 2b , randomize , double-blind , parallel-group study . Subjects unresectable pleural peritoneal malignant mesothelioma randomize 2:1 ratio receive either tremelimumab placebo . Approximately 564 subject enrol study center multiple country . The study consist screen period , treatment period , 90-day follow-up period safety , long-term survival follow-up period .</brief_summary>
	<brief_title>Randomized , Double-blind Study Comparing Tremelimumab Placebo Subjects With Unresectable Malignant Mesothelioma</brief_title>
	<detailed_description>This Phase 2b , randomize , double-blind , parallel-group study . Subjects unresectable pleural peritoneal malignant mesothelioma randomize 2:1 ratio receive either tremelimumab placebo . Randomization stratify EORTC status ( low-risk v high-risk ) , line therapy ( second v third ) , anatomical site ( pleural v peritoneal ) . This study plan use EORTC stratify subject high low risk group order ensure balance randomization different treatment group . For subject pemetrexed contraindicate tolerated approve therapy ( eg , peritoneal mesothelioma ) , prior therapy first-line platinum-based regimen require . Approximately 564 subject enrol study center multiple country . The study consist screen period , treatment period , 90-day follow-up period .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically and/or cytologically confirm pleural peritoneal malignant mesothelioma . Disease amenable curative surgery ; Age 18 time consent ; ECOG Performance status 01 ; Progressed previous receipt 12 prior systemic treatment advance disease include firstline pemetrexed ( antifolate ) base regimen combination platinum agent ; Recovered toxicity associate prior treatment ; Measurable disease ; Adequate bone marrow , hepatic , renal function Received prior monoclonal antibody CTLA4 , program cell death 1 ( PD1 ) program cell death 1 ligand 1 ( PDL1 ) ; History chronic inflammatory autoimmune disease ; Active , untreated central nervous system ( CNS ) metastasis ; History malignancy unless subject diseasefree least 3 year ; Active history diverticulitis . Note diverticulosis permit ; Active history inflammatory bowel disease ( eg , colitis , Crohn 's ) , irritable bowel disease , celiac disease serious gastrointestinal chronic condition associate diarrhea . Active history systemic lupus erythematosis Wegener 's granulomatosis ; History sarcoidosis syndrome ; Currently receive systemic corticosteroid immunosuppressive medication ; The last dose prior chemotherapy radiation therapy ( exception palliative radiotherapy ) receive less 2 week prior randomization ; Any unresolved toxicity NCI CTCAE Grade â‰¥ 2 previous anticancer therapy ; exception vitiligo alopecia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>tremelimumab</keyword>
	<keyword>pleural , peritoneal</keyword>
	<keyword>malignant mesothelioma</keyword>
	<keyword>CTLA-4</keyword>
</DOC>